Physician profile
Donald A Freeman
NPI 1841075710
$3,147.58
in general payments reported to CMS, 2019-2025
16 companies · $1,328 in 2025
The $1,328 reported for 2025 was more than what 86% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $805 · 2024: $1,014 · 2025: $1,328.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,148.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,147.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $572.12 | 2023-2025 | Caplyta |
| Abbvie INC. | $565.44 | 2023-2025 | |
| Neurocrine Biosciences, INC. | $455.41 | 2023-2024 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $445.89 | 2023-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Alkermes, INC. | $240.30 | 2023-2025 | Aristada, Lybalvi, Vivitrol |
| E.R. Squibb & Sons, L.L.C. | $211.21 | 2025 | Cobenfy |
| Otsuka America Pharmaceutical, INC. | $160.65 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $136.07 | 2023-2025 | Invega Sustenna, Spravato |
| Axsome Therapeutics, INC. | $81.40 | 2025 | Auvelity |
| Indivior INC. | $55.99 | 2023-2025 | Sublocade, Perseris |
| Noven Therapeutics, LLC | $46.70 | 2024 | Xelstrym, Secuado |
| Vanda Pharmaceuticals INC. | $45.58 | 2023 | Hetlioz, Fanapt |
| Acadia Pharmaceuticals INC | $44.54 | 2025 | Nuplazid |
| Corium, LLC | $34.47 | 2024 | Azstarys |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $30.63 | 2025 | Rejoyn |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $21.18 | 2024 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donald Freeman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.